Form 4: AN2 Therapeutics Director Gilbert Lynn Marks Reports Stock Option Grant
SEC Form 4 Filing
Director Gilbert Lynn Marks of AN2 Therapeutics, Inc. reports the acquisition of stock options.
Summary
- Gilbert Lynn Marks, a director of AN2 Therapeutics, Inc., filed a Form 4 with the SEC.
- The filing reports the grant of stock options to Marks on June 19, 2024.
- Marks received options to purchase 64,503 shares of common stock at an exercise price of $2 per share.
- The options vest on the earlier of the one-year anniversary of the grant date or the day prior to the company's next annual stockholder meeting, contingent upon continuous service.
- Marks also has a power of attorney designating certain individuals at AN2 Therapeutics and Latham & Watkins LLP to act on his behalf for SEC filings.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and there is no inherent positive or negative sentiment associated with it.
Industry Context
This is a standard SEC filing related to executive compensation. Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023/12/14 | Date of Power of Attorney execution. |
| 2024/06/19 | Date of stock option grant and transaction. |
| 2024/06/21 | Date of Form 4 signature. |
| 2034/06/18 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.